Recent Quotes

My Watchlist

Indicators

Travere Therapeutics Inc (NQ: TVTX )

18.75 -0.28 (-1.47%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,307,779
Open	18.76
Bid (Size)	18.75 (2)
Ask (Size)	19.65 (2)
Prev. Close	19.03
Today's Range	18.55 - 19.22
52wk Range	5.120 - 20.33
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

November 12, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

3 Under-the-Radar Healthcare Companies

November 11, 2024

While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.

Via MarketBeat

Performance

YTD	+96.13%	+96.13%
1 Month	+7.51%	+7.51%
3 Month	+112.10%	+112.10%
6 Month	+179.85%	+179.85%
1 Year	+228.95%	+228.95%

More News

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

November 07, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

A Preview Of Travere Therapeutics's Earnings

October 30, 2024

Via Benzinga

Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)

October 21, 2024

Via Benzinga

Breaking Down Travere Therapeutics: 23 Analysts Share Their Views

October 16, 2024

Via Benzinga

Travere Therapeutics Announces Proposed Public Offering of Common Stock

November 07, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

November 04, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Third Quarter 2024 Financial Results

October 31, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

October 10, 2024

Via Benzinga

Where Travere Therapeutics Stands With Analysts

September 27, 2024

Via Benzinga

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

October 26, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'

October 23, 2024

Via Benzinga

Travere Therapeutics to Report Third Quarter 2024 Financial Results

October 21, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session

October 17, 2024

Via Benzinga

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

October 17, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

October 14, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm

October 11, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease

October 09, 2024

Via Investor's Business Daily

Micron To $150? Here Are 10 Top Analyst Forecasts For Friday

September 27, 2024

Via Benzinga

Costco, Scholastic And 3 Stocks To Watch Heading Into Friday

September 27, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

September 26, 2024

Via Benzinga

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

September 26, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 12, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

September 10, 2024

From Travere Therapeutics, Inc.

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.